Renal Biomarkers Market 2021 : Develop Unique Solutions will Bolster Growth

“The Global Renal Biomarkers, Insights, Size, Growth, Challenges, Opportunities, Emerging Trends, and Geographic Regions, Forecast Period: to Renal Biomarkers”

Request Here For PDF Brochure

A biomarker is an organism’s biological signature that is calculated as an index of normal biological processes. Renal biomarkers are useful for detecting acute and permanent kidney injuries as well as diagnosing multiple kidney diseases. A good renal biomarker should be able to detect kidney disorders early on.
In 2019, the global renal biomarkers market is anticipated to have a valuation of US$ 1,094.5 million and is forecasted to attain a valuation of US$ 1,894.2 million by 2027.

Drivers

During the forecast period, the global renal biomarkers market is expected to grow due to the rising prevalence of chronic kidney diseases. According to data from the European Renal Association – European Dialysis and Transplant Association in 2018, over 850 million people worldwide have kidney disease in some form.
Furthermore, the demand is projected to expand as the rate of development of chronic kidney disease in children increases. According to the research ‘Risk Factors and Rate of Progression of CKD in Infants,’ released in Kidney International Reports in June 2019, 38 percent of children have chronic kidney disease progression within two years of follow-up.

In 2018, the North American region held a leading position in the global renal biomarkers market, contributing about 32.5% of market share, and was followed by Europe.

Restraints

The global renal biomarkers market is expected to be hampered by low sensitivity and specificity of biomarkers. Some renal biomarkers, such as L-18, are more specific but not very sensitive, whereas others, such as osteopontin, are highly sensitive but not specific.

Furthermore, the market’s growth is expected to be limited by the use of unreliable, imperfect gold standards. The gold standard is serum creatinine, despite its low sensitivity and specificity. Serum creatinine does not distinguish between renal injury and non-renal causes like hemodynamic (obstructive uropathy) mediated changes. In addition, serum creatinine is less effective in renal injury and recovery.

Opportunities

Market players may concentrate on collaborating with academia to identify new biomarkers that will aid drug development.

Furthermore, R&D in renal biomarkers is expected to contribute to market growth. Researchers from NLC India Limited, the National Institute of Mental Health and Neurosciences, and the MDRF (Madras Diabetes Research Foundation) in Chennai, India, announced in February 2020 that they had discovered a urine-based biomarker, Micro albuminuria, which could be used to predict diabetic kidney failure early.

In 2018, the functional biomarkers segment of the global renal biomarkers market had a valuation of US$ 543.6 million and is projected to attain a valuation of US$ 1,057.3 million by 2027 with a CAGR of 7.6 percent over the forecast period.

Key Takeaways

The development of feline renal biomarkers is a priority for market participants. Antech symmetric dimethylarginine (SDMA), a feline renal biomarker for early diagnosis, staging, and monitoring of chronic kidney disease, was launched by Mars Petcare’s Antech Diagnostics in February 2020.

Renal biomarker research and development is also a priority for the market’s major players. SphingoTec GmbH, for example, published novel study findings of its patented kidney function biomarker penKid in BMC Emergency Medicine in December 2019.

Key Developments

The market’s major players are concentrating on introducing new products in order to extend their product range. SphingoTec GmbH, for example, unveiled IB10 sphingotest penKid, a CE-IVD-marked point-of-care test for Proenkephalin, a renal biomarker, in January 2020.

To broaden their product range, industry players are now focusing on the acceptance and introduction of new biomarkers. BioPorto A/S announced in November 2019 that it will complement its paediatric 510(k) application in the United States. The NGAL Test (a biomarker test) for paediatric risk assessment of acute kidney injury has received additional evidence from the FDA for regulatory approval.

Major Key Players Include In Renal Biomarkers Market: Beckman Coulter, Inc., (Danaher Corporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S, Astute Medical, Inc., Randox Laboratories Ltd., and SphingoTec GmbH.

Buy instant copy of this research report with Flat US $ 2000 Off@ – https://www.coherentmarketinsights.com/promo/buynow/3551

Main points in Renal Biomarkers Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Renal Biomarkers Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Renal Biomarkers Industry Impact

Chapter 2 Global Renal Biomarkers Competition by Types, Applications, and Top Regions and Countries
2.1 Global Renal Biomarkers (Volume and Value) by Type
2.3 Global Renal Biomarkers (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Renal Biomarkers Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Renal Biomarkers Market Analysis
Chapter 6 East Asia Renal Biomarkers Market Analysis
Chapter 7 Europe Renal Biomarkers Market Analysis
Chapter 8 South Asia Renal Biomarkers Market Analysis
Chapter 9 Southeast Asia Renal Biomarkers Market Analysis
Chapter 10 Middle East Renal Biomarkers Market Analysis
Chapter 11 Africa Renal Biomarkers Market Analysis
Chapter 12 Oceania Renal Biomarkers Market Analysis
Chapter 13 South America Renal Biomarkers Market Analysis
Chapter 14 Company Profiles and Key Figures in Renal Biomarkers Business
Chapter 15 Global Renal Biomarkers Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

Request for a Sample Report 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com